SAB Biotherapeutics Announces New Appointments to its Board of Directors
16.12.2020 15:27:00 EET | Business Wire | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors.
“We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Both Drs. Mohindru and Turner are joining SAB at a pivotal time as we continue to advance a new class of immunotherapies that leverage the native human immune response and match the evolution of human disease. We look forward to their contributions as we develop our robust pipeline, spanning multiple therapeutic areas, using our novel technology platform.”
Dr. Mohindru is a senior biopharmaceutical executive with several years of industry leadership as well as Wall Street experience. Most recently, she was the CEO of CereXis, a clinical-stage biopharmaceutical company developing treatments for rare tumors. Previously, Dr. Mohindru was Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics (Nasdaq: CARA), a company focused on developing therapies for pruritus and pain. Earlier, she served as Chief Strategy Officer at Curis, Inc. (Nasdaq: CRIS), where she was instrumental in the development of overall strategy for its oncology focused pipeline. Dr. Mohindru also spent several years as an equity research analyst covering the biotechnology sector at ThinkEquity, LLC, Credit Suisse and UBS. She also co-founded Immtox LLC, a privately-held biotechnology company, and was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health). Currently, she also serves as a Member of the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Dr. Mohindru received her PhD in Neurosciences from Northwestern University.
Dr. Mervyn Turner has nearly 35 years of experience in pharmaceutical drug discovery, research and development, licensing and business development, emerging markets strategy development and implementation. He currently operates his own consulting firm, MJ Turner Consulting, where he counsels biotech, pharma, venture capital and investment banking firms. He spent 27 years at Merck & Co. Inc., holding positions of increasing responsibility in Merck Research Laboratories before joining the company’s Executive Committee as Chief Strategy Officer. Since his retirement from Merck & Co., he is currently an Advisor to Bay City Capital, a San Francisco-based venture firm, to Bridge Medicines, a commercial incubator for early stage innovation based in New York City, and to Adagene, a China-based therapeutic antibody company. Dr Turner is also a member of the Board of EnGeneIC (Sydney, Australia), and the Chairman of the Board of LUNAC. He also serves on the Scientific Advisory Boards of Blade Therapeutics and Spinogenix. Additionally, Dr. Turner is a Senior Advisor to the Healthcare group of Lazard, a leading financial services and investment banking firm. He holds his PhD in Chemistry from the University of Sheffield.
“I am excited to have the opportunity to join the Board of SAB, to help foster the adoption of the company’s unique capabilities in meeting the therapeutic needs of both the current, and future pandemics,” said Mervyn Turner, PhD. “I also look forward to helping to drive the SAB platform into novel therapeutic areas outside infectious disease, where polyclonal antibody technology offers unique capabilities in areas of significant unmet medical need.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed with initial funding supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). In addition to COVID-19, the company’s pipeline also includes programs in Type 1 diabetes, organ transplant and influenza. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005549/en/
Contact information
Melissa Ullerich
Tel: 605-695-8350
mullerich@sabbiotherapeutics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Announces Tech World @ CES 2027: Defining the Next Era of Hybrid AI7.10.2026 16:01:00 EEST | Press release
Lenovo, the global technology powerhouse, today announced that its annual global innovation event will return to CES® 2027 in Las Vegas. Hosted at Sphere and part of the CES Keynote lineup, Tech World will bring together a visionary lineup of speakers and breakthrough innovations with a first-of-its-kind immersive technology and music experience. As well as unveiling the latest in Lenovo’s innovations, Tech World will unite global technology leaders and leading voices on stage to discuss the future of AI. Together, they will explore how hybrid AI can empower people and unlock new possibilities for business and society. As demand grows for responsible AI leadership, the event will provide a defining moment at the start of 2027 to consider AI’s role in unlocking human potential, sustaining the planet, and driving global progress. “AI is entering a new phase, where every individual and every enterprise should be empowered to transform data into real value,” said Yuanqing Yang, Lenovo Chai
Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment7.10.2026 16:00:00 EEST | Press release
Rivercell, a Paris-based biotechnology and AI company building its own data infrastructure on how human cells respond to any treatment and training a world model of the cell that can predict those responses, today announced a $25 million seed round led by HV. HCVC, Alven and Bpifrance Digital Venture also participated in the round, which will fund the scale-up of Rivercell’s proprietary data generation platform, the expansion of its wet lab in Paris (a lab working with chemicals and biological samples), and the launch of its AI Virtual Cell program. Being indication-agnostic, Rivercell's world model can drive groundbreaking discovery across any cell behavior that leads to disease because it learns the underlying rules of how human cells respond to drugs and genetic changes, not the features of a single disease. Rivercell was started in summer 2025 by CEO Yann Fleureau, the engineer-turned-entrepreneur behind AI company Cardiologs, joined in 2026 by CSO Eric Durand, an AI scientist and
NTT DATA Opens AI Factory Munich Where Clients Can Validate their AI in a Live Environment7.10.2026 16:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today opened the NTT DATA AI Factory Munich, a real-world environment where clients can test how their AI applications will perform at scale before they invest in broad deployments. Unlike a traditional AI demonstration or innovation lab, the AI Factory Munich operates within a live data center environment (NTT Global Data Centers' Munich 2 Data Center), allowing clients to evaluate AI workloads against the infrastructure, security, data, governance and operational requirements they will face in production. AI deployments typically stall between pilots that prove an idea and enterprise-scale production that delivers value. To bridge this gap, the AI Factory Munich leverages NTT DATA’s capabilities from consulting, infrastructure and AI platforms to managed services, data centers and its global partner ecosystem. Among active partners, NVIDIA provides an accelerated computing platform, including NVIDIA Blackwell
Print Infrastructure Is the Biggest Zero Trust Gap CIOs Haven’t Closed, Survey Finds7.10.2026 15:30:00 EEST | Press release
Vasion today released new research revealing a security gap hiding in plain sight across enterprise IT: CIOs and IT leaders know their print environments carry risk, but print remains largely outside their Zero Trust strategies even as failures continue to disrupt business operations. According to an independent survey of 500+ enterprise CIOs and senior IT leaders commissioned by Vasion through Censuswide, 54% of respondents describe their print environment as “actively managed, with known and accepted risks.” At the same time, 61% report that print or document workflow failures disrupt their business at least once a week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007677295/en/ Print Infrastructure Is the Biggest Zero Trust Gap CIOs Haven’t Closed, Survey Finds The finding points to a broader issue: print may not be viewed as broken, but it remains an accepted area of exposure and operational friction. The gap become
Oscilloquartz expands OSAinside ™ Series OSA 5400 TimeCard ™ with advanced server-integrated timing capabilities7.10.2026 15:00:00 EEST | Press release
Oscilloquartz today announced significant new capabilities for its OSAinside™ Series OSA 5400 TimeCard™, expanding the flexibility and performance of server-integrated timing for defense, data center, telecom and finance applications. With support for multiple deployment architectures and timing sources, the enhanced OSA 5400 TimeCard™ enables organizations to integrate highly accurate synchronization directly into commercial off-the-shelf (COTS) and purpose-built servers, reducing reliance on dedicated external timing appliances. Available as the OSA 5400 TimeCard™ and the OSA 5400 TAP TimeCard™, the platform supports PCIe Precision Time Measurement (PTM), multi-band L1/L5 GNSS with NavIC and Galileo OSNMA, advanced jamming and spoofing detection and multiple oscillator options for precise server-level synchronization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007831264/en/ Oscilloquartz’s enhanced OSA 5400 TimeCard
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom